GH Guardant Health: Earnings growth forecast for next year

Graphic logo of Guardant Health, Inc. (GH)

The EPS growth trajectory for next year confirms the pricing power potential of Guardant Health, Inc. (GH) driven by its unique early-stage cancer tests. The implementation of robotic DNA sequencing systems is accelerating diagnostics, while adherence to ESG standards minimizes the environmental footprint of the laboratories. The value of 34.80 characterizes this valuation parameter, capturing current analyst expectations for future stock returns.

Guardant Health Inc (GH): Consensus forecast of earnings per share growth for next year from 07/04/2022 to 11/13/2026

Analytical breakdowns and data insights for company guardanthealth.com (GH)

- price and consensus price forecast:
Price Chart Guardant360|GH - Analyst Median Target
- company stock capitalization data:
Market Capitalization Guardant Health|GH - Company Buyout Price
- book capitalization indicators:
Net Assets per Single Share Guardant Health|GH - Book Valuation of Business|Market Capitalization to Book Value Ratio guardanthealth.com|GH - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Equity Ratio Guardant Health, Inc.|GH - Long-Term Debt to Capital|Short-Term Debt to Capital Guardant Health|GH - Company Aggregate Debts|Debt to Book Capitalization Ratio Guardant Health|GH - Company Long-Term Loans and Borrowings|Company Short-Term Debts Guardant Health|Quick Ratio guardanthealth.com
- net income and valuation ratios data:
GH - Net Profit|Expected Profit Guardant Health, Inc.|GH - Price to Earnings Multiple|Projected Price to Earnings Guardant Health, Inc.|GH - Company Value to Earnings Growth Ratio|Enterprise Value to EBITDA Ratio Guardant Health|GH - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Guardant Health|GH - Earnings per share for the trailing year|Quarterly EPS earnings growth guardanthealth.com|GH - Earnings per share growth rate in current year|Earnings growth forecast for next year Guardant Health, Inc.
- revenue and sales details:
GH - Revenue and Sales Volume|Company Projected Revenue Guardant360|GH - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple Guardant Health
Basic company analysis:GH, Guardant360
Brand item of guardanthealth.com

The consensus earnings growth forecast for the upcoming period measures the expected change in EPS, allowing investors to isolate the fundamental trend from market noise. This projected net income trajectory reflects the capitalization of future successes for Guardant Health, Inc. (GH), where earnings growth potential depends directly on the efficiency of scaling high-tech laboratories and optimizing costs through the digitalization of reporting.

Competitor analysis for Guardant Health, Inc.

Net earnings per share growth forecast for next year Caris|Veracyte Diagnostics (VCYT) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year CELC|Consensus forecast of earnings per share growth for next year grail.com|Net earnings per share growth forecast for next year Myriad Genetics MYGN|Consensus forecast of earnings per share growth for next year Castle Biosciences Inc (CSTL)|Burning Rock Biotech Ltd. - Earnings growth forecast for next year|Net earnings per one share growth forecast for next year VolitionRx Limited (VNRX)|BDSX (Biodesix, Inc.) - Expected earnings per share growth for next year|precipiodx.com (PRPO) - Earnings growth forecast for next year|CHEK (Check-Cap Ltd) - Earnings growth forecast for next year|Earnings growth forecast for next year Mainz Biomed NV|Net earnings per share growth forecast for next year OncoCyte Corp. (OCX)